Previous 10 | Next 10 |
Constellation Pharmaceuticals ([[CNST]] +5.4%) appoints Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the company’s commercial organizatio...
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for ...
Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...
Gainers: Obalon Therapeutics (OBLN) +116%, Oncternal Therapeutics (ONCT) +77%, Fate Therapeutics (FATE) +41%, Constellation Pharmaceuticals (CNST) +33%, Nkarta (NKTX) +28%.Losers: scPharmaceuticals (SCPH) -33%, Aptose Biosciences (APTO) -...
Source: Press release"We are pleased both with the response rates and consistency of the results we are seeing in MANIFEST,"says Constellation Pharmaceuticals (CNST) CEO Jigar Raythatha. "In addition, we are excited by results from our translational studies that suggest that CPI-0610 may...
67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeks CPI-0610 demonst rated activity , both as a monotherapy and as add on to ruxolitinib , in seco...
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor eve...
Company printed above expectation earnings and revenues in latest quarter, mirroring increases in Canada. Company has a new CEO that has 30 years of branding experience and will help to advance the company's goals. The new Israel medical products are selling well and a new partner...
Image source: The Motley Fool. Constellation Pharmaceuticals (NASDAQ: CNST) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Constellation Pharmaceuticals (CNST) Q3 2020 Earnings Call Tr...
Gainers: Universal Security Instruments (UUU) +69%.Polar Power (POLA) +37%.Rekor Systems (REKR) +35%.Entercom Communications (ETM) +33%.Pinterest (PINS) +29%.Inphi (IPHI) +28%.Forte Biosciences (FBRX) +21%.Meta Financial Group (CASH) +19%.Novus Therapeutics (NVUS) +18%.Dig...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...